Roth Capital Forecasts Weaker Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Roth Capital dropped their Q1 2025 earnings estimates for Globus Medical in a note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now anticipates that the medical device company will earn $0.75 per share for the quarter, down from their previous estimate of $0.80. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.84 EPS, Q3 2025 earnings at $0.88 EPS, FY2025 earnings at $3.44 EPS, FY2026 earnings at $4.30 EPS and FY2027 earnings at $4.76 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.18. The company had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.57 earnings per share.

GMED has been the topic of several other reports. Wells Fargo & Company upped their price target on shares of Globus Medical from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Roth Mkm upped their target price on Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus lifted their price target on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Bank of America boosted their price target on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada raised their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.55.

Globus Medical Stock Down 2.0 %

Shares of NYSE:GMED opened at $81.78 on Wednesday. Globus Medical has a 52-week low of $49.33 and a 52-week high of $87.22. The stock has a market cap of $11.14 billion, a price-to-earnings ratio of 122.06, a PEG ratio of 1.99 and a beta of 1.19. The business has a 50-day moving average price of $79.54 and a 200-day moving average price of $73.17.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently made changes to their positions in the business. State Street Corp boosted its position in shares of Globus Medical by 2.3% in the 3rd quarter. State Street Corp now owns 3,570,726 shares of the medical device company’s stock valued at $255,450,000 after purchasing an additional 81,371 shares during the period. Burgundy Asset Management Ltd. increased its position in shares of Globus Medical by 1.4% in the second quarter. Burgundy Asset Management Ltd. now owns 2,514,891 shares of the medical device company’s stock worth $172,245,000 after acquiring an additional 35,054 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Globus Medical by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,885,061 shares of the medical device company’s stock worth $134,893,000 after acquiring an additional 21,935 shares in the last quarter. Magnetar Financial LLC increased its position in shares of Globus Medical by 1.7% in the second quarter. Magnetar Financial LLC now owns 1,718,487 shares of the medical device company’s stock worth $117,699,000 after acquiring an additional 29,200 shares in the last quarter. Finally, Geneva Capital Management LLC raised its holdings in shares of Globus Medical by 1.1% during the third quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company’s stock valued at $114,330,000 after acquiring an additional 18,117 shares during the period. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $87.00, for a total transaction of $217,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,500 shares of company stock worth $7,674,950. 18.54% of the stock is owned by company insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.